Checkout
Cart: $0.00 - (0 items )

Ulcerative Colitis News

News-Medical.Net Ulcerative Colitis News Feed

Latest Ulcerative Colitis News and Research

The Allen Institute today announced the launch of the Allen Institute for Immunology, a new division of the Institute that is dedicated to studying the human immune system.
Posted: December 13, 2018, 8:08 am
The Allen Institute today announced the launch of the Allen Institute for Immunology, a new division of the Institute that is dedicated to studying the human immune system.
Posted: December 13, 2018, 7:16 am
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.
Posted: December 8, 2018, 4:29 am
TARGET PharmaSolutions, Inc., a company focused on real-world evidence, is pleased to announce that Bristol Myers Squibb has entered into a strategic partnership for TARGET-IBD.
Posted: December 5, 2018, 11:13 am
Cellix Biosciences Inc., a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for the development of CLX-103, a novel molecular conjugate of mesalamine for the treatment of mild to moderate ulcerative colitis.
Posted: October 30, 2018, 5:39 am
AbbVie, a research-based global biopharmaceutical company, today announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis.
Posted: October 23, 2018, 7:36 am
The way we breathe may affect how well our memories are consolidated (i.e. reinforced and stabilized). If we breathe through the nose rather than the mouth after trying to learn a set of smells, we remember them better, researchers at Karolinska Institutet in Sweden report in The Journal of Neuroscience.
Posted: October 22, 2018, 7:17 pm
Takeda Pharmaceutical Company Limited today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous induction therapy.
Posted: October 22, 2018, 8:40 am
Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.
Posted: October 22, 2018, 5:55 am
Children who develop inflammatory bowel disease (ulcerative colitis or Crohn's disease) have an increased risk of death, both in childhood and later in life, a study from Karolinska Institutet in Sweden published in the journal Gastroenterology reports.
Posted: October 19, 2018, 6:49 am

Write a Reply or Comment:

Time limit is exhausted. Please reload the CAPTCHA.

Back to top
Contact
close slider